MLL-AF9 Expression in Hematopoietic Stem Cells Drives a Highly Invasive AML Expressing EMT-Related Genes Linked to Poor Outcome

Vaia Stavropoulou; Susanne Kaspar; Laurent Brault; Mathijs A. Sanders; Sabine Juge; Stefano Morettini; Alexandar Tzankov; Michelina Iacovino; I. Jun Lau; Thomas A. Milne; Hélène Royo; Michael Kyba; Peter J M Valk; Antoine H F M Peters; Juerg Schwaller

doi:10.1016/j.ccell.2016.05.011

MLL-AF9 Expression in Hematopoietic Stem Cells Drives a Highly Invasive AML Expressing EMT-Related Genes Linked to Poor Outcome

Vaia Stavropoulou, Susanne Kaspar, Laurent Brault, Mathijs A. Sanders, Sabine Juge, Stefano Morettini, Alexandar Tzankov, Michelina Iacovino, I. Jun Lau, Thomas A. Milne, Hélène Royo, Michael Kyba, Peter J M Valk, Antoine H F M Peters, Juerg Schwaller

Pediatric Blood & Marrow Transplant & Cellular Therapy

Research output: Contribution to journal › Article › peer-review

127 Scopus citations

Abstract

To address the impact of cellular origin on acute myeloid leukemia (AML), we generated an inducible transgenic mouse model for MLL-AF9-driven leukemia. MLL-AF9 expression in long-term hematopoietic stem cells (LT-HSC) in vitro resulted in dispersed clonogenic growth and expression of genes involved in migration and invasion. In vivo, 20% LT-HSC-derived AML were particularly aggressive with extensive tissue infiltration, chemoresistance, and expressed genes related to epithelial-mesenchymal transition (EMT) in solid cancers. Knockdown of the EMT regulator ZEB1 significantly reduced leukemic blast invasion. By classifying mouse and human leukemias according to Evi1/EVI1 and Erg/ERG expression, reflecting aggressiveness and cell of origin, and performing comparative transcriptomics, we identified several EMT-related genes that were significantly associated with poor overall survival of AML patients.

Original language	English (US)
Pages (from-to)	43-58
Number of pages	16
Journal	Cancer Cell
Volume	30
Issue number	1
DOIs	https://doi.org/10.1016/j.ccell.2016.05.011
State	Published - Jul 11 2016

Bibliographical note

Funding Information:
We thank Dr. J.L. Hess (Ann Arbor, USA) for the pMSCV-MLL-AF9 plasmid, and E. Traunecker, T. Krebs, U. Schneider and his team for FACS and animal husbandry support. We acknowledge the FMI members: M.B. Stadler for computational support, T. Roloff and his team for transcriptional profiling, J.F. Spetz, P. Kopp, and B. Kuchemann for generating iMLL-AF9 mice, and J. Tjeertes for discussions. A.H.F.M.P.’s laboratory was supported by: Novartis Research Foundation , SystemsX.ch (Cell plasticity), and EMBO YIP program . J.S.’s laboratory was supported by: Swiss National Science Foundation ( SNF-31003A_130661 & 31003A_149714/1 ), Swiss Cancer League ( OCS-2357-02-2009 , OCS-02778-02-2011 , KFS-3019-08-2012 ), Wilhelm Sander Foundation (Munich), Novartis Research Foundation , Swiss Bridge Foundation , and the Gertrude Von Meissner Foundation Basel. H.R. thanks the FP7-PEOPLE-2013-IEF grant. T.A.M. was supported by a Medical Research Council (UK) Molecular Hematology Unit grant MC_UU_12009/6 and I.-J.L. by an MRC UK Clinical Research Training Fellowship MR/M003221/1 . T.A.M. is a founding shareholder of Oxstem Oncology, a subsidiary company of OxStem Ltd.

Publisher Copyright:
© 2016 Elsevier Inc.

Keywords

EMT
MLL-AF9
acute myeloid leukemia
invasion
poor overall survival
stem cell

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Publisher link

10.1016/j.ccell.2016.05.011

Find It

Find It at U of M Libraries

Cite this

Stavropoulou, V., Kaspar, S., Brault, L., Sanders, M. A., Juge, S., Morettini, S., Tzankov, A., Iacovino, M., Lau, I. J., Milne, T. A., Royo, H., Kyba, M., Valk, P. J. M., Peters, A. H. F. M., & Schwaller, J. (2016). MLL-AF9 Expression in Hematopoietic Stem Cells Drives a Highly Invasive AML Expressing EMT-Related Genes Linked to Poor Outcome. Cancer Cell, 30(1), 43-58. https://doi.org/10.1016/j.ccell.2016.05.011

Stavropoulou, V, Kaspar, S, Brault, L, Sanders, MA, Juge, S, Morettini, S, Tzankov, A, Iacovino, M, Lau, IJ, Milne, TA, Royo, H, Kyba, M, Valk, PJM, Peters, AHFM & Schwaller, J 2016, 'MLL-AF9 Expression in Hematopoietic Stem Cells Drives a Highly Invasive AML Expressing EMT-Related Genes Linked to Poor Outcome', Cancer Cell, vol. 30, no. 1, pp. 43-58. https://doi.org/10.1016/j.ccell.2016.05.011

@article{64ef7bfd3df0420189e282475ee54d3e,

title = "MLL-AF9 Expression in Hematopoietic Stem Cells Drives a Highly Invasive AML Expressing EMT-Related Genes Linked to Poor Outcome",

abstract = "To address the impact of cellular origin on acute myeloid leukemia (AML), we generated an inducible transgenic mouse model for MLL-AF9-driven leukemia. MLL-AF9 expression in long-term hematopoietic stem cells (LT-HSC) in vitro resulted in dispersed clonogenic growth and expression of genes involved in migration and invasion. In vivo, 20% LT-HSC-derived AML were particularly aggressive with extensive tissue infiltration, chemoresistance, and expressed genes related to epithelial-mesenchymal transition (EMT) in solid cancers. Knockdown of the EMT regulator ZEB1 significantly reduced leukemic blast invasion. By classifying mouse and human leukemias according to Evi1/EVI1 and Erg/ERG expression, reflecting aggressiveness and cell of origin, and performing comparative transcriptomics, we identified several EMT-related genes that were significantly associated with poor overall survival of AML patients.",

keywords = "EMT, MLL-AF9, acute myeloid leukemia, invasion, poor overall survival, stem cell",

author = "Vaia Stavropoulou and Susanne Kaspar and Laurent Brault and Sanders, {Mathijs A.} and Sabine Juge and Stefano Morettini and Alexandar Tzankov and Michelina Iacovino and Lau, {I. Jun} and Milne, {Thomas A.} and H{\'e}l{\`e}ne Royo and Michael Kyba and Valk, {Peter J M} and Peters, {Antoine H F M} and Juerg Schwaller",

note = "Funding Information: We thank Dr. J.L. Hess (Ann Arbor, USA) for the pMSCV-MLL-AF9 plasmid, and E. Traunecker, T. Krebs, U. Schneider and his team for FACS and animal husbandry support. We acknowledge the FMI members: M.B. Stadler for computational support, T. Roloff and his team for transcriptional profiling, J.F. Spetz, P. Kopp, and B. Kuchemann for generating iMLL-AF9 mice, and J. Tjeertes for discussions. A.H.F.M.P.{\textquoteright}s laboratory was supported by: Novartis Research Foundation , SystemsX.ch (Cell plasticity), and EMBO YIP program . J.S.{\textquoteright}s laboratory was supported by: Swiss National Science Foundation ( SNF-31003A_130661 & 31003A_149714/1 ), Swiss Cancer League ( OCS-2357-02-2009 , OCS-02778-02-2011 , KFS-3019-08-2012 ), Wilhelm Sander Foundation (Munich), Novartis Research Foundation , Swiss Bridge Foundation , and the Gertrude Von Meissner Foundation Basel. H.R. thanks the FP7-PEOPLE-2013-IEF grant. T.A.M. was supported by a Medical Research Council (UK) Molecular Hematology Unit grant MC_UU_12009/6 and I.-J.L. by an MRC UK Clinical Research Training Fellowship MR/M003221/1 . T.A.M. is a founding shareholder of Oxstem Oncology, a subsidiary company of OxStem Ltd. Publisher Copyright: {\textcopyright} 2016 Elsevier Inc.",

year = "2016",

month = jul,

day = "11",

doi = "10.1016/j.ccell.2016.05.011",

language = "English (US)",

volume = "30",

pages = "43--58",

journal = "Cancer Cell",

issn = "1535-6108",

publisher = "Cell Press",

number = "1",

}

TY - JOUR

T1 - MLL-AF9 Expression in Hematopoietic Stem Cells Drives a Highly Invasive AML Expressing EMT-Related Genes Linked to Poor Outcome

AU - Stavropoulou, Vaia

AU - Kaspar, Susanne

AU - Brault, Laurent

AU - Sanders, Mathijs A.

AU - Juge, Sabine

AU - Morettini, Stefano

AU - Tzankov, Alexandar

AU - Iacovino, Michelina

AU - Lau, I. Jun

AU - Milne, Thomas A.

AU - Royo, Hélène

AU - Kyba, Michael

AU - Valk, Peter J M

AU - Peters, Antoine H F M

AU - Schwaller, Juerg

N1 - Funding Information: We thank Dr. J.L. Hess (Ann Arbor, USA) for the pMSCV-MLL-AF9 plasmid, and E. Traunecker, T. Krebs, U. Schneider and his team for FACS and animal husbandry support. We acknowledge the FMI members: M.B. Stadler for computational support, T. Roloff and his team for transcriptional profiling, J.F. Spetz, P. Kopp, and B. Kuchemann for generating iMLL-AF9 mice, and J. Tjeertes for discussions. A.H.F.M.P.’s laboratory was supported by: Novartis Research Foundation , SystemsX.ch (Cell plasticity), and EMBO YIP program . J.S.’s laboratory was supported by: Swiss National Science Foundation ( SNF-31003A_130661 & 31003A_149714/1 ), Swiss Cancer League ( OCS-2357-02-2009 , OCS-02778-02-2011 , KFS-3019-08-2012 ), Wilhelm Sander Foundation (Munich), Novartis Research Foundation , Swiss Bridge Foundation , and the Gertrude Von Meissner Foundation Basel. H.R. thanks the FP7-PEOPLE-2013-IEF grant. T.A.M. was supported by a Medical Research Council (UK) Molecular Hematology Unit grant MC_UU_12009/6 and I.-J.L. by an MRC UK Clinical Research Training Fellowship MR/M003221/1 . T.A.M. is a founding shareholder of Oxstem Oncology, a subsidiary company of OxStem Ltd. Publisher Copyright: © 2016 Elsevier Inc.

PY - 2016/7/11

Y1 - 2016/7/11

N2 - To address the impact of cellular origin on acute myeloid leukemia (AML), we generated an inducible transgenic mouse model for MLL-AF9-driven leukemia. MLL-AF9 expression in long-term hematopoietic stem cells (LT-HSC) in vitro resulted in dispersed clonogenic growth and expression of genes involved in migration and invasion. In vivo, 20% LT-HSC-derived AML were particularly aggressive with extensive tissue infiltration, chemoresistance, and expressed genes related to epithelial-mesenchymal transition (EMT) in solid cancers. Knockdown of the EMT regulator ZEB1 significantly reduced leukemic blast invasion. By classifying mouse and human leukemias according to Evi1/EVI1 and Erg/ERG expression, reflecting aggressiveness and cell of origin, and performing comparative transcriptomics, we identified several EMT-related genes that were significantly associated with poor overall survival of AML patients.

AB - To address the impact of cellular origin on acute myeloid leukemia (AML), we generated an inducible transgenic mouse model for MLL-AF9-driven leukemia. MLL-AF9 expression in long-term hematopoietic stem cells (LT-HSC) in vitro resulted in dispersed clonogenic growth and expression of genes involved in migration and invasion. In vivo, 20% LT-HSC-derived AML were particularly aggressive with extensive tissue infiltration, chemoresistance, and expressed genes related to epithelial-mesenchymal transition (EMT) in solid cancers. Knockdown of the EMT regulator ZEB1 significantly reduced leukemic blast invasion. By classifying mouse and human leukemias according to Evi1/EVI1 and Erg/ERG expression, reflecting aggressiveness and cell of origin, and performing comparative transcriptomics, we identified several EMT-related genes that were significantly associated with poor overall survival of AML patients.

KW - EMT

KW - MLL-AF9

KW - acute myeloid leukemia

KW - invasion

KW - poor overall survival

KW - stem cell

UR - http://www.scopus.com/inward/record.url?scp=84979788984&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84979788984&partnerID=8YFLogxK

U2 - 10.1016/j.ccell.2016.05.011

DO - 10.1016/j.ccell.2016.05.011

M3 - Article

C2 - 27344946

AN - SCOPUS:84979788984

SN - 1535-6108

VL - 30

SP - 43

EP - 58

JO - Cancer Cell

JF - Cancer Cell

IS - 1

ER -

MLL-AF9 Expression in Hematopoietic Stem Cells Drives a Highly Invasive AML Expressing EMT-Related Genes Linked to Poor Outcome

Abstract

Bibliographical note

Keywords

UN SDGs

Publisher link

Find It

Other files and links

Fingerprint

Cite this